Yorkshire Collaborative Small Cell Lung Cancer Study

Submission date	Recruitment status	Prospectively registered
19/08/2002	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
19/08/2002	Completed	Results
Last Edited	Condition category	Individual participant data
24/10/2019	Cancer	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr - -

Contact details

UKCCCR Register Co-ordinator MRC Clinical Trials Unit 222 Euston Road London United Kingdom NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers TH/SMC

Study information

Scientific Title

Yorkshire Collaborative Small Cell Lung Cancer Study

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Not Specified

Participant information sheet

Health condition(s) or problem(s) studied

Lung (small cell)

Interventions

Good/moderate-prognosis patients: Patients receive chemotherapy with Ifosfamide, etoposide, mensa and vincristine (EIMV) for three courses. Patients with greater than 50% response are randomised to either:

- 1. Group A: No mandatory treatment, radiotherapy is optional.
- 2. Group B: Three further courses of EIMV chemotherapy plus optional radiotherapy.

Poor-prognosis patients: Chemotherapy is at the physicians discretion. If chemotherapy is chosen single agent etoposide or EIMV chemotherapy is recommended.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1994

Completion date

01/04/1995

Eligibility

Key inclusion criteria

- 1. Small cell lung cancer confirmed by histological or bronchial brush or aspirate cytology.
- 2. Aged <75 years
- 3. Normal renal and hepatic function
- 4. No evidence of brain metastases
- 5. No previous specific anti-cancer treatment for current disease
- 6. No other malignant disease, except basal cell carcinoma and in situ carcinoma of the cervix

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

Not provided at time of registration

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1994

Date of final enrolment

01/04/1995

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

UKCCCR Register Co-ordinator

London United Kingdom NW1 2DA

Sponsor information

Organisation

Northern and Yorkshire Clinical Trials and Research Unit (UK)

Sponsor details

_

Leeds United Kingdom

-

Sponsor type

Research organisation

Funder(s)

Funder type

Research organisation

Funder Name

Northern & Yorkshire Clinical Trials & Research Unit (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration